Biologics Introduces Clinical Policy and Therapeutic Intelligence Office
News May 01, 2013
The department has been established to advance the company’s clinical expertise efforts as it continues to distinguish itself as a leader in complex disease medical management and pharmacy services, specifically within the oncology sector. Leading this initiative will be Ann Steagall, BSN, RN, OCN, Director of Clinical Policy and Mike James, RPh, PhD, Director of Therapeutic Intelligence.
Primary objectives for the department will be to lead the clinical oversight committee, develop care plans and clinical assessments, and facilitate training for clinical and non-clinical Biologics team members and clients.
“Over the years we have discussed the importance of Biologics leading with our clinical expertise both internally and externally. Additionally, it has long been our objective for Biologics to be considered a teaching organization,” said Stuart Frantz, President & Chief Executive Officer at Biologics. “Combine those two concepts and you have the Clinical Policy and Therapeutic Intelligence Office.”
As Director of Clinical Policy, Ann will lead the coordination of all plan language reviews, an important component of the Care Integration program. She will also continue to serve on the Oncology Board of Advisors.
As Director of Therapeutic Intelligence, Mike will assess all new drug entries and expanded uses which include pipeline monitoring. He will support the development of disease specific whitepapers for client and internal education, and will serve on the Oncology Board of Advisors.
Immune Response Restored in Patients with Melanoma Thanks to New CompoundNews
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.READ MORE